title: Design-Based Peptidomimetic Ligand Discovery to Target HIV TAR RNA Using Comparative Analysis of Different Docking Methods.
abstract: Discovering molecules capable of binding to HIV trans-activation responsive region (TAR) RNA thereby disrupting its interaction with Tat protein is an attractive strategy for developing novel antiviral drugs. Computational docking is considered as a useful tool for predicting binding affinity and conducting virtual screening. Although great progress in predicting protein-ligand interactions has been achieved in the past few decades, modeling RNA-ligand interactions is still largely unexplored due to the highly flexible nature of RNA. In this work, we performed molecular docking study with HIV TAR RNA using previously identified cyclic peptide L22 and its analogues with varying affinities toward HIV-1 TAR RNA. Furthermore, sarcosine scan was conducted to generate derivatives of CGP64222, a peptide-peptoid hybrid with inhibitory activity on Tat/TAR RNA interaction. Each compound was docked using CDOCKER, Surflex-Dock and FlexiDock to compare the effectiveness of each method. It was found that FlexiDock energy values correlated well with the experimental Kd values and could be used to predict the affinity of the ligands toward HIV-1 TAR RNA with a superior accuracy. Our results based on comparative analysis of different docking methods in RNA-ligand modeling will facilitate the structure-based discovery of HIV TAR RNA ligands for antiviral therapy.
authors.forename: Junjie
authors.initials: J
authors.lastname: Fu
authors.forename: Amy
authors.initials: A
authors.lastname: Xia
authors.forename: Yao
authors.initials: Y
authors.lastname: Dai
authors.affiliation: Department of Medicinal Chemistry and Department of Radiation Oncology, University of Florida, Gainesville, FL, 32610, United States. xqi@cop.ufl.edu.
authors.forename: Xin
authors.initials: X
authors.lastname: Qi
mesh_terms: D019380:Anti-HIV Agents / Q000302:isolation & purification / Q000378:metabolism*; D055808:Drug Discovery / Q000379:methods*; D016325:HIV Long Terminal Repeat; D015497:HIV-1 / Q000187:drug effects; D006801:Humans; D062105:Molecular Docking Simulation / Q000379:methods*; D010456:Peptides, Cyclic / Q000302:isolation & purification / Q000378:metabolism*; D057786:Peptidomimetics / Q000302:isolation & purification / Q000378:metabolism*; D011485:Protein Binding; D012367:RNA, Viral / Q000378:metabolism*
chemical_list: D019380:Anti-HIV Agents; D010456:Peptides, Cyclic; D057786:Peptidomimetics; D012367:RNA, Viral